Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction Treatment options for metastatic colorectal cancer (mCRC) in late-line settings remain limited, particularly in patients with microsatellite stable disease. Antibody-drug conjugates (ADCs) targeting tumour-specific pathways represent an...
Introduction Colorectal liver metastases (CRLM) remain a major determinant of mortality in colorectal cancer, with hepatic resection offering the best chance of long-term survival in selected patients. However,...
Introduction Oligometastatic cancer represents an intermediate disease state characterized by limited metastatic burden and a potentially distinct therapeutic window for metastases-directed therapy (MDT). As MDT becomes increasingly integrated...
Introduction Early detection of pancreatic ductal adenocarcinoma (PDAC) remains one of the most critical unmet needs in gastroenterology. Multibiomarker panels like PancreaSure represent an important step toward improving...
Introduction Biliary tract cancers (BTCs), including intrahepatic, perihilar and distal cholangiocarcinoma as well as gallbladder cancer, remain among the most aggressive gastrointestinal malignancies. Curative treatment has traditionally relied...
Introduction Gastric neuroendocrine neoplasms (gNENs) represent a heterogeneous group of tumors with rising incidence, encompassing well-differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-neuroendocrine neoplasms...
Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors...
Introduction Metastatic pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with a 5-year survival of approximately 3%. Current first-line chemotherapy offers limited benefit and significant toxicity....
Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors...
Introduction Colorectal cancer liver metastases represent a major determinant of survival in colorectal cancer, affecting more than half of patients. While hepatic resection remains the cornerstone of curative...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.